# name
Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy

# metadata.dc.contributor.author[].value
Spanish Group For The Study Of Glomerular Diseases (GLOSEN)

# metadata.dc.description.abstract[].value
Background C3 glomerulopathy is a rare kidney disease, which makes it difficult to collect large cohorts of patients to better understand its variability. The aims of this study were to describe the clinical profiles and patterns of progression of kidney disease. Methods This was a retrospective, observational cohort study. Patients diagnosed with C3 glomerulopathy between 1995 and 2020 were enrolled. Study population was divided into clinical profiles by combining the following predictors: eGFR under/above 30 ml/min per 1.73 m(2), proteinuria under/above 3.5 g/d, and histologic chronicity score under/above 4. The change in eGFR and proteinuria over time was evaluated in a subgroup with consecutive measurements of eGFR and proteinuria. Results One hundred and fifteen patients with a median age of 30 years (interquartile range 19-50) were included. Patients were divided into eight clinical profiles. Kidney survival was significantly higher in patients with a chronicity score<4 and proteinuria <3.5 g/d, both in those presenting with an eGFR under/above 30 ml/min per 1.73m(2). The median eGFR slope of patients who reached kidney failure was26.5 ml/min per 1.73m(2) per year (interquartile range 21.6 to 217). Patients who showed a reduction in proteinuria over time did not reach kidney failure. On the basis of the rate of eGFR decline, patients were classified as faster eGFR decline (>= 5 ml/min per 1.73m(2) per year), slower (<5 ml/min per 1.73m(2) per year), and those without decline. A faster eGFR decline was associated with higher probability of kidney failure. Conclusions Kidney survival is significantly higher in patients with a chronicity score < 4 and proteinuria < 3.5 g/d regardless of baseline eGFR, and a faster rate of decline in eGFR is associated with higher probability of kidney failure.

# metadata.dc.publisher[].value
Ovid Technologies (Wolters Kluwer Health)

# metadata.dc.rights[].value
cc by (c) Caravaca Fontán, Fernando et al., 2023

# metadata.dc.source[].value
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

# metadata.dc.title[].value
Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy